Mavacamten in obstructive hypertrophic cardiomyopathy: a profile of its use

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest Tina Nie and Yahiya Syed are salaried employees of Adis International Ltd/Springer Nature and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here.

Abstract

Mavacamten (Camzyos^®), an oral, once-daily cardiac myosin inhibitor, is an important new option for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). In the USA, mavacamten is the first approved drug for the treatment of adults with symptomatic New York Heart Association (NYHA) class II–III obstructive HCM to improve functional capacity and symptoms. In a pivotal phase 3 trial in this patient population, mavacamten improved exercise capacity, symptom burden, and left ventricular outflow tract obstruction compared with placebo. Mavacamten was generally well tolerated, with the most common adverse events being dizziness and syncope. Longer-term data up to 84 weeks demonstrated that the efficacy of mavacamten was maintained with no new safety concerns. Mavacamten may increase the risk of heart failure due to systolic dysfunction and therefore, individualized dosage and close monitoring is required.  

© Springer Nature Switzerland AG 2023